Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents

Department of Pharmaceutical Sciences, University of Salerno, Italy.
Best Practice & Research: Clinical Endocrinology & Metabolism (Impact Factor: 4.91). 03/2009; 23(1):117-31. DOI: 10.1016/j.beem.2009.02.001
Source: PubMed

ABSTRACT Cannabinoids (the active components of Cannabis sativa) and their derivatives have received renewed interest in recent years due to their diverse pharmacological activities. In particular, cannabinoids offer potential applications as anti-tumour drugs, based on the ability of some members of this class of compounds to limit cell proliferation and to induce tumour-selective cell death. Although synthetic cannabinoids may have pro-tumour effects in vivo due to their immunosuppressive properties, predominantly inhibitory effects on tumour growth and migration, angiogenesis, metastasis, and also inflammation have been described. Emerging evidence suggests that agonists of cannabinoid receptors expressed by tumour cells may offer a novel strategy to treat cancer. In this chapter we review the more recent results generating interest in the field of cannabinoids and cancer, and provide novel suggestions for the development, exploration and use of cannabinoid agonists for cancer therapy, not only as palliative but also as curative drugs.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In light of the adverse side-effects of opioids, cannabinoid receptor agonists may provide an effective alternative for the treatment of cancer pain. This study examined the potency and efficacy of synthetic CB1 and CB2 receptor agonists in a murine model of tumor pain. Intraplantar injection of the CB1 receptor agonist arachidonylcyclopropylamide (ED(50) of 18.4 μg) reduced tumor-related mechanical hyperalgesia by activation of peripheral CB1 but not CB2 receptors. Similar injection of the CB2 receptor agonist AM1241 (ED50 of 19.5 μg) reduced mechanical hyperalgesia by activation of peripheral CB2 but not CB1 receptors. Both agonists had an efficacy comparable with that of morphine (intraplantar), but their analgesic effects were independent of opioid receptors. Isobolographic analysis of the coinjection of arachidonylcyclopropylamide and AM1241 determined that the CB1 and CB2 receptor agonists interacted synergistically to reduce mechanical hyperalgesia in the tumor-bearing paw. These data extend our previous findings that the peripheral cannabinoid receptors are a promising target for the management of cancer pain and mixed cannabinoid receptor agonists may have a therapeutic advantage over selective agonists.
    Behavioural pharmacology 05/2011; 22(5-6):607-16. DOI:10.1097/FBP.0b013e3283474a6d · 2.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rimonabant (SR141716), a cannabinoid CB1 receptor antagonist known for anti-obesity activity, has more recently been shown to inhibit tumor cell growth. Here we demonstrated the antitumor potential of SR141716 in leukemia-derived cell lines and its low toxicity in normal cells (PBMC). SR141716 (1-20microM range of doses) reduced Jurkat and U937 cell number by activating death signals as well as affecting cell cycle progression. The most prominent response in U937 to SR141716 was a G(0)/G(1) block, while in Jurkat cells there was activation of cell death processes. SR141716-treated cells exhibited the morphological and biochemical features of apoptosis and to some extent necrosis. Apoptotic mode of cell death was confirmed in both cell lines by analysis of cell morphology, phosphatidylserine exposure and DNA fragmentation. Moreover, the drug was found to induce an early and robust mitochondrial membrane depolarization. In Jurkat cells the apoptotic process was typically caspase-dependent, while in U937 caspase-independent pathways were also activated. The contribution of PARP activation to SR141716-induced apoptosis in U937 was suggested by protein PARylation, AIF release and apoptosis reversal by PARP inhibitors. Moreover, SR141716 negatively modulated, especially in U937, the PI3K/AKT pathways. In conclusion, our data indicate that SR141716 elicits alternative response and/or cell death pathways depending on the cell type affected.
    Biochemical pharmacology 08/2010; 80(3):370-80. DOI:10.1016/j.bcp.2010.04.023 · 4.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die Fortschritte der modernen Onkologie mit ihren vielfältigen und komplexen Möglichkeiten der Diagnose und Therapie von Krebserkrankungen haben dazu geführt, dass mehr Patientinnen und Patienten geheilt werden. Dafür müssen viele Betroffene allerdings eine beeinträchtigende Therapiephase bewältigen und erleben für die Dauer ihres geretteten Lebens bleibende Krankheitsauswirkungen und Rezidivängste. Auch die Fortschritte der palliativen Onkologie, die mehr Krebskranken ein längeres Leben mit der Erkrankung ermöglichen, fordern eine längere Adaptationsleistung an das Leben mit einer lebensbedrohlichen chronischen Krankheit und oft nebenwirkungsträchtigen Langzeittherapien. In dieser prozesshaften und mehrdimensionalen Auseinandersetzung mit Krankheit und Kranksein spielt für viele Patientinnen und Patienten und ihr soziales Umfeld der Umgang mit der sog. Komplementärmedizin eine wichtige Rolle. Dieser Beitrag gibt einen Überblick über die wichtigsten Verfahren.
    best practice onkologie 04/2013; 5(4):44-54. DOI:10.1007/s11654-010-0250-0